Product Revenues, Net was Incyte’s largest product and service line in fiscal 2025, bringing in $4.35B of $5.14B (85%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenues, Net | — | $3.17B | $3.62B | $4.35B | ||||||
| Jakafi | $2.41B | — | — | — | ||||||
| Product Royalty Revenues | — | $523.48M | $579.33M | $636.91M | ||||||
| Jakavi Royalty Revenues | $331.58M | — | — | — | ||||||
| Olumiant | — | — | — | — | ||||||
| Olumiant Royalty Revenues | $134.55M | — | — | — | ||||||
| Milestone & Contract Revenues | $165.00M | $7.00M | $43.00M | $150.00M | ||||||
| Iclusig | $105.84M | — | — | — | ||||||
| Pemazyre | $83.45M | — | — | — | ||||||
| Opzelura | $128.74M | — | — | — | ||||||
| Minjuvi/Monjuvi | $19.65M | — | — | — | ||||||
| Tabrecta Royalty Revenues | $15.41M | — | — | — | ||||||
| Minjuvi | — | — | — | — | ||||||
| Tabrecta | — | — | — | — | ||||||
| Pemazyre Royalty Revenues | $1.21M | — | — | — | ||||||
| Other Revenues | — | — | — | — | ||||||
| Total | $3.39B | $3.70B | $4.24B | $5.14B |
Incyte brought in $5.14B from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 21.2% from $4.24B in fiscal 2024. Product Revenues, Net was the largest at $4.35B (84.7%), ahead of Product Royalty Revenues at $636.91M (12.4%) and Milestone & Contract Revenues at $150.00M (2.9%).
Compared with fiscal 2024, Milestone & Contract Revenues grew fastest, up 248.8% to $150.00M. Every line above 2% of revenue grew.
Incyte began breaking out Product Revenues, Net in fiscal 2023, when it brought in $3.17B. Incyte stopped reporting Jakafi ($2.41B in fiscal 2022), Jakavi Royalty Revenues ($331.58M in fiscal 2022), Olumiant Royalty Revenues ($134.55M in fiscal 2022) and six others as separate lines.
United States was Incyte’s largest region in fiscal 2025, bringing in $4.80B of $5.14B (93%).
| Geography | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| United States | $3.20B | $3.51B | $3.97B | $4.80B | |||
| U.S | — | — | — | — | |||
| Europe | $147.00M | $175.87M | $260.44M | $323.73M | |||
| Other Countries | — | $4.91M | $6.21M | $17.57M | |||
| Total | $3.35B | $3.70B | $4.24B | $5.14B |
Incyte brought in $5.14B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 21.2% from $4.24B in fiscal 2024. United States was the largest at $4.80B (93.4%), ahead of Europe at $323.73M (6.3%) and Other Countries at $17.57M (0.3%).
Compared with fiscal 2024, Europe grew 24.3% to $323.73M and United States grew 20.8% to $4.80B.
Incyte began breaking out Other Countries in fiscal 2023, when it brought in $4.91M.
Incyte (INCY) reports its revenue by product and service and by geography. In fiscal 2025, Product Revenues, Net was its largest product and service line, bringing in $4.35B (84.7% of the total), followed by Product Royalty Revenues at $636.91M (12.4%).
Product Revenues, Net was Incyte's largest product and service line in fiscal 2025, bringing in $4.35B, or 84.7% of the $5.14B total across its three product and service lines.
United States was Incyte's largest region in fiscal 2025, bringing in $4.80B, or 93.4% of the $5.14B total across its three regions.
Among Incyte's product and service lines that make up at least 2% of revenue, Milestone & Contract Revenues grew fastest in fiscal 2025, up 248.8% from $43.00M to $150.00M.
Every figure comes from Incyte's annual financial filings, as reported. Each line keeps the name Incyte gives it, and years follow its fiscal calendar.
Incyte's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.